ImpediMed receives order for 16 SOZO units to address lymphoedema

By Trevor Hoey. Published at Apr 1, 2020, in Technology

ImpediMed Limited (ASX:IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), has received the first order of 16 units under the recently announced national purchasing agreement with a US oncology care network for its SOZO® Digital Health Platform and Lymphoedema Prevention Program.

This is a significant development for the group, and while it is currently in a trading halt and this news will not be reflected in movements in its share price today, the company could receive support on Friday when it is due to recommence trading.

Based on the depth of buyers currently in the queue to buy stock when the company recommences trading there could be a significant rerating.

The initial order of 16 SOZO units will establish a comprehensive Lymphoedema Prevention Program in key centres from this nationally recognised oncology care network.

In commenting on the significance for the group in terms of national distribution, chief executive Richard Carreon said, “We believe these centres will develop the model from which we will jointly expand our program nationally.”

95% reduction in lymphoedema progression at one year.

The national purchasing agreement, which was announced on 23 March, allows 1,200 physicians at 470 cancer treatment locations across the US access to SOZO and ImpediMed’s BIS (L-Dex®) lymphoedema assessment.

Together, these physicians treat over 1 million patients annually.

The Lymphoedema Prevention Program utilises ImpediMed's Test, Trigger, TreatTM protocol for early detection and intervention of cancer-related lymphoedema.

Routine lymphoedema testing of cancer survivors uses the company's SOZO device with BIS (LDex) technology.

A significant increase in a patient's L-Dex score is a trigger to evaluate the patient and initiate intervention.

ImpediMed's PREVENT Trial, the largest multi-site, randomised controlled trial ever performed to study lymphoedema prevention, showed that this protocol resulted in a 95% reduction in lymphoedema progression at one year.

Currently, one in three at-risk cancer survivors will develop secondary lymphoedema related to their cancer treatment, costing the US healthcare system approximately $7 billion every year.

The aim of the Lymphoedema Prevention Program is to help educate healthcare providers and patients that with the proper protocols in place, lymphoedema can be detected and managed before it becomes a debilitating chronic condition.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why Finfeed.com is Australia’s leading small cap publication

Founded seven years ago, Finfeed.com is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise.

Finfeed.com provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more.

Finfeed.com is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!

X